Filtered By:
Specialty: Drugs & Pharmacology
Condition: Metabolic Syndrome

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 38 results found since Jan 2013.

A Combination of Atorvastatin and Aspirin Enhances the Pro-Regenerative Interactions of Marrow Stromal Cells and Stroke-Derived Monocytes In Vitro
Conclusion: Atorvastatin, alone and in combination with aspirin can promote anti-inflammatory effect by modulating the secretome profile of Mo and MSCs. Our results suggest that stroke trials involving the use of intravenous MSCs should consider the effect of aspirin and atorvastatin, both of which are administered to the majority of hospitalized ischemic stroke patients.
Source: Frontiers in Pharmacology - April 20, 2021 Category: Drugs & Pharmacology Source Type: research

Aging, the metabolic syndrome, and ischemic stroke: redefining the approach for studying the blood-brain barrier in a complex neurological disease.
Abstract The blood-brain barrier (BBB) has many important functions in maintaining the brain's immune-privileged status. Endothelial cells, astrocytes, and pericytes have important roles in preserving vasculature integrity. As we age, cell senescence can contribute to BBB compromise. The compromised BBB allows an influx of inflammatory cytokines to enter the brain. These cytokines lead to neuronal and glial damage. Ultimately, the functional changes within the brain can cause age-related disease. One of the most prominent age-related diseases is ischemic stroke. Stroke is the largest cause of disability and is thi...
Source: Advances in Pharmacology - October 15, 2014 Category: Drugs & Pharmacology Authors: Lucke-Wold BP, Logsdon AF, Turner RC, Rosen CL, Huber JD Tags: Adv Pharmacol Source Type: research

Crocins for Ischemic Stroke: A Review of Current Evidence
Crocins (CRs) and the related active constituents derived from Crocus sativus L. (Saffron) have demonstrated protective effects against cerebral ischemia and ischemic stroke, with various bioactivities including neuroprotection, anti-neuroinflammation, antioxidant, and cardiovascular protection. Among CRs, crocin (CR) has been shown to act on multiple mechanisms and signaling pathways involved in ischemic stroke, including mitochondrial apoptosis, nuclear factor kappa light chain enhancer of B cells pathway, S100 calcium-binding protein B, interleukin-6 and vascular endothelial growth factor-A. CR is generally safe and wel...
Source: Frontiers in Pharmacology - August 5, 2022 Category: Drugs & Pharmacology Source Type: research

Hyperglycaemic Metabolic Complications of Ischemic Brain: Current therapeutics, anti-diabetics and stem cell therapy
CNS Neurol Disord Drug Targets. 2022 Jun 9. doi: 10.2174/1871527321666220609200852. Online ahead of print.ABSTRACTStroke is the leading cause of morbidity and mortality in diabetic patients. Diabetes alters endothelial function and disrupts brain pathways, resulting in a variety of systemic metabolic complications. Diabetics not only have impaired neurotransmission, but they also have progressive neurodegeneration, which leads to long-term neurological complications. Diabetes risk factors and physiology alter the frequency and severity of cardiovascular and cerebrovascular events, necessitating more hospitalizations. Strok...
Source: CNS and Neurological Disorders Drug Targets - June 13, 2022 Category: Drugs & Pharmacology Authors: Vishal Chavda Snehal Patel Source Type: research

Estimation of the long-term cardiovascular events using ukpds risk engine in metabolic syndrome patients
V Shivakumar, A Kandhare, AR Rajmane, M Adil, P Ghosh, LB Badgujar, MN Saraf, SL BodhankarIndian Journal of Pharmaceutical Sciences 2014 76(2):174-178Long-term cardiovascular complications in metabolic syndrome are a major cause of mortality and morbidity in India and forecasted estimates in this domain of research are scarcely reported in the literature. The aim of present investigation is to estimate the cardiovascular events associated with a representative Indian population of patients suffering from metabolic syndrome using United Kingdom Prospective Diabetes Study risk engine. Patient level data was collated from 567...
Source: Indian Journal of Pharmaceutical Sciences - April 25, 2014 Category: Drugs & Pharmacology Authors: V ShivakumarA KandhareAR RajmaneM AdilP GhoshLB BadgujarMN SarafSL Bodhankar Source Type: research

20-hete in the regulation of vascular and cardiac function
Publication date: Available online 23 July 2018Source: Pharmacology & TherapeuticsAuthor(s): Petra Rocic, Michal Laniado SchwartzmanAbstract20-HETE, the ω-hydroxylation product of arachidonic acid catalyzed by enzymes of the cytochrome P450 (CYP) 4A and 4F gene families, is a bioactive lipid mediator with potent effects on the vasculature including stimulation of smooth muscle cell contractility, migration and proliferation as well as activation of endothelial cell dysfunction and inflammation. Clinical studies have shown elevated levels of plasma and urinary 20-HETE in human diseases and conditions such as hypertension, ...
Source: Pharmacology and Therapeutics - July 24, 2018 Category: Drugs & Pharmacology Source Type: research

Angiotensin Receptor Blockers Versus Angiotensin Converting Enzyme Inhibitors for the Treatment of Arterial Hypertension and the Role of Olmesartan
AbstractBlood pressure lowering by all classes of antihypertensive drugs is accompanied by significant reductions of stroke and major cardiovascular (CV) events. Drugs acting on the renin –angiotensin–aldosterone system, such as angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs), showed similar benefit on major CV events to other antihypertensive medications. In real-world practice, ARBs reduced by 10% the incidence of CV mortality, non-fata l myocardial infarction, non-fatal stroke and provided superior protection against CV events than ACEIs in high-risk patients. Despite simila...
Source: Advances in Therapy - December 27, 2018 Category: Drugs & Pharmacology Source Type: research

Uric acid in metabolic and cerebrovascular disorders: a review.
CONCLUSION: UA, which is associated with arterial hypertension and cardiovascular diseases, represents one of the indicators of oxidative homeostasis. Increasing concentrations represent a status of active inflammation which is observed with metabolic and cerebrovascular diseases. PMID: 31845632 [PubMed - as supplied by publisher]
Source: Current Vascular Pharmacology - December 16, 2019 Category: Drugs & Pharmacology Authors: Cortese F, Scicchitano P, Meliota G, Giordano P, Ciccone MM Tags: Curr Vasc Pharmacol Source Type: research

CC Chemokine Receptors and Chronic Inflammation--Therapeutic Opportunities and Pharmacological Challenges.
Abstract Chemokines are a family of low molecular weight proteins with an essential role in leukocyte trafficking during both homeostasis and inflammation. The CC class of chemokines consists of at least 28 members (CCL1-28) that signal through 10 known chemokine receptors (CCR1-10). CC chemokine receptors are expressed predominantly by T cells and monocyte-macrophages, cell types associated predominantly with chronic inflammation occurring over weeks or years. Chronic inflammatory diseases including rheumatoid arthritis, atherosclerosis, and metabolic syndrome are characterized by continued leukocyte infiltration...
Source: Pharmacological Reviews - January 10, 2013 Category: Drugs & Pharmacology Authors: White GE, Iqbal AJ, Greaves DR Tags: Pharmacol Rev Source Type: research

Drug treatments to restore vascular function and diabesity.
Abstract Over the last decades, an escalating rate of type 2 diabetes has paralleled an epidemic rise in the prevalence of obesity. Both diabetes and obesity confer an increased risk of cardiovascular comorbidities, including hypertension, coronary artery disease and stroke. Vascular dysfunction, represented by impaired endothelial release of vasodilator substances or defective smooth muscle vasodilator reactivity, is the early stage of the process leading to atherosclerosis and a common finding in patients with diabesity. It is understandable, therefore, that effective treatments for diabesity should restore vasc...
Source: Annales Pharmaceutiques Francaises - January 1, 2013 Category: Drugs & Pharmacology Authors: Cardillo C Tags: Ann Pharm Fr Source Type: research

Insulin Resistance, Small LDL Particles, and Risk for Atherosclerotic Disease.
Abstract There is a global epidemic of obesity, metabolic syndrome, and diabetes mellitus. Insulin resistance (IR) is etiologic for both metabolic syndrome and diabetes mellitus. IR induces a broad range of toxic systemic effects, including dyslipidemia, hypertension, hyperglycemia, increased production of advanced glycosylation end products, increased inflammatory tone, as well as a prothrombotic and pro-oxidative state. Patients with IR are highly vulnerable to the development of accelerated atherosclerosis as well its clinical sequelae, including coronary artery disease and myocardial infarction, carotid artery...
Source: Current Vascular Pharmacology - April 25, 2013 Category: Drugs & Pharmacology Authors: Toth PP Tags: Curr Vasc Pharmacol Source Type: research

The Role of Statins in the Treatment of Type 2 Diabetes Mellitus: an Update.
Abstract The prevalence of type 2 diabetes mellitus (T2DM) is increasing worldwide. T2DM is associated with both microvascular (neuropathy, nephropathy and retinopathy) and macrovascular complications [coronary artery disease (CAD), stroke, carotid artery disease and peripheral artery disease (PAD)]. Apart from acting on diabetic dyslipidemia, statins were shown to exert beneficial effects on several diabetic complications as well as other cardiovascular (CVD) risk predictors such as endothelial dysfunction, inflammation, oxidative stress, chronic kidney disease (CKD), non-alcoholic fatty liver disease (NAFLD), me...
Source: Current Pharmaceutical Design - September 12, 2013 Category: Drugs & Pharmacology Authors: Niki Katsiki, Vasilios G Athyros, Asterios Karagiannis, Dimitri P Mikhailidis Tags: Curr Pharm Des Source Type: research

Metabolic Syndrome and Non-Cardiac Vascular Diseases: an Update from Human Studies.
Abstract The metabolic syndrome (MetS) is characterized by a cluster of risk factors including central obesity, hypertension, dyslipidemia and insulin resistance, The MetS is associated with an increased risk for cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). Several international organizations have defined MetS using different diagnostic criteria that produced discrepancies in the results of previous studies, thus leading to the latest Joint Interim Societies (JIS) MetS definition. Other risk factors than the diagnostic criteria that have been associated with MetS include lipid abnormalities, u...
Source: Current Pharmaceutical Design - December 5, 2013 Category: Drugs & Pharmacology Authors: Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP Tags: Curr Pharm Des Source Type: research

Coffee: A Selected Overview of Beneficial or Harmful Effects on the Cardiovascular System?
Abstract With a history that began in 800 A.D., coffee is the most popular drink known and as a result, the issues regarding its physiologic effects deserve attention. Maintaining alertness is a well-known benefit and in addition, the cardiovascular (CV) effects of the active compounds, which include polyphenols and caffeine, must be considered. Genetics are relevant and where slow caffeine metabolism is inherent, the risk of nonfatal myocardial (MI) has been shown to be increased. Overall risk for coronary heart disease (CHD) is not supported and unless there is excessive intake, congestive heart failure (CHF) is...
Source: Current Vascular Pharmacology - October 2, 2014 Category: Drugs & Pharmacology Authors: Whayne Jr TF Tags: Curr Vasc Pharmacol Source Type: research